<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03226223</url>
  </required_header>
  <id_info>
    <org_study_id>#7347</org_study_id>
    <nct_id>NCT03226223</nct_id>
  </id_info>
  <brief_title>Pharmacogenetics of Naltrexone for Stimulant Abuse</brief_title>
  <official_title>Using Pharmacogenetics to Better Evaluate Naltrexone for Treating Stimulant Abuse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This investigation will be the first study assessing genetic modulation of naltrexone's NTX&#xD;
      effects upon the abuse liability of a stimulant drug (methamphetamine). The study team will&#xD;
      assess the ability of oral NTX to block the reinforcing and positive subjective effects of&#xD;
      intranasal (IN) methamphetamine (30mg/70kg). This investigation could identify an important&#xD;
      Gene x Pharmacological interaction, contributing to the personalization of stimulant abuse&#xD;
      pharmacotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A recent meta-analysis concluded that the OPRM1 A118G SNP (rs1799971) significantly moderates&#xD;
      the treatment efficacy of Naltrexone (NTX) in treating alcohol abuse, increasing the&#xD;
      treatment efficacy by over 2-fold among G-allele carriers (AG/GG). The proposed application&#xD;
      would be the first to investigate the moderating effect of this genotype in the efficacy of&#xD;
      NTX to treat stimulant abuse. More specifically, the study team proposes to investigate the&#xD;
      interaction between NTX and intranasal (IN) methamphetamine (30mg/70kg). Participants who&#xD;
      meet DSM criteria for mild-to-severe stimulant use disorder (N=up to 70) will complete 4&#xD;
      testing sessions where drug effects are tested following pretreatment with NTX (0, 50 mg).&#xD;
      Naltrexone pretreatment effects upon the abuse liability of IN methamphetamine will be&#xD;
      assessed using self-report measurements of positive subjective effects and drug&#xD;
      self-administration. Medication effects on these validated predictors of abuse potential will&#xD;
      be compared between A118G A allele homozygotes (AA) and G-allele carriers (AG/GG; an&#xD;
      anticipated 25% of the total sample), in order to assess genetic moderation of treatment&#xD;
      outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2016</start_date>
  <completion_date type="Actual">July 30, 2020</completion_date>
  <primary_completion_date type="Actual">July 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants will complete two testing sessions in which the effects of oral naltrexone (0 mg &amp; 50 mg) will be tested in combination with intranasal methamphetamine. Participants will complete two testing sessions (naltrexone 0 mg + Methamphetamine &amp; naltrexone 50 mg + methamphetamine), in randomized order.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants and study staff conducting the lab sessions will be blinded to the treatment condition (i.e., naltrexone 0 mg or 50 mg)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Methamphetamine Self-Administration</measure>
    <time_frame>1 day.</time_frame>
    <description>To assess the reinforcing effects of methamphetamine, participants complete a drug self-administration procedure. The outcome measure for this procedure is the number of operant responses (clicks on a mouse) participant are willing to make in order to receive drug (methamphetamine).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive Subjective Effects of Methamphetamine.</measure>
    <time_frame>1 day</time_frame>
    <description>Participant ratings of methamphetamine &quot;Liking,&quot; on a 100 mm visual analog scale. Participants are asked to indicate on a 100 mm line the extent to which they agree with the description of the drug provided. The 0 mm end of the line indicates &quot;Not at All,&quot; while the 100 mm indicates &quot;Extremely.&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Substance Use Disorders</condition>
  <condition>Methamphetamine Abuse</condition>
  <arm_group>
    <arm_group_label>Naltrexone 0 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This aim assess the effects of pretreatment with 0 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This aim assess the effects of pretreatment with 50 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal Methamphetamine</intervention_name>
    <description>Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)</description>
    <arm_group_label>Naltrexone 0 mg</arm_group_label>
    <arm_group_label>Naltrexone 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female age 21 to 50 years&#xD;
&#xD;
          2. DSM-5 criteria for mild-to-severe stimulant use disorder, along with intravenous,&#xD;
             intranasal or smoked use of amphetamine-type stimulants in amounts equal to or greater&#xD;
             than administered in the current study.&#xD;
&#xD;
          3. Able to give written informed consent to participate.&#xD;
&#xD;
          4. Females must be either post-menopausal, surgically sterilized, or using an acceptable&#xD;
             method of contraception (double-barrier method like a condom with a spermicidal&#xD;
             lubricant) to participate in this study.&#xD;
&#xD;
          5. Racially Caucasian or of European descent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently seeking treatment for a substance use disorder.&#xD;
&#xD;
          2. DSM-5 criteria for moderate-to-severe substance use disorders (except those involving&#xD;
             cocaine, amphetamines and nicotine).&#xD;
&#xD;
          3. Psychiatric condition that may affect the participants' ability to provide informed&#xD;
             consent (e.g., psychotic disorder), or make participation hazardous for the&#xD;
             participant or study staff (e.g., severe depression/suicidality, or risk of violence).&#xD;
&#xD;
          4. Uncontrolled neurological, cardiovascular, and hepatic diseases, active tuberculosis,&#xD;
             or any other disorder that might make administration of study medications hazardous.&#xD;
&#xD;
          5. Gastrointestinal or renal disease that would significantly impair absorption,&#xD;
             metabolism or excretion of study drug, or require medication or medical treatment.&#xD;
&#xD;
          6. Current treatment with a psychotropic medication that in the physician's judgement&#xD;
             would interfere with the study endpoints.&#xD;
&#xD;
          7. History of allergy, adverse reaction, or sensitivity to amphetamines.&#xD;
&#xD;
          8. Medical conditions that may make study participation hazardous:&#xD;
&#xD;
               -  History of seizures or cardiac risk conditions (unstable angina, cardiac&#xD;
                  arrhythmias, chest pain, strong palpitations (subjectively defined as the feeling&#xD;
                  that the heart is beating too hard, too fast, skipping a beat, or fluttering).&#xD;
&#xD;
               -  Elevated liver function tests (i.e., AST and ALT &gt; 3 times the upper limit of&#xD;
                  normal).&#xD;
&#xD;
               -  Impaired renal function (creatinine &gt; 1.2).&#xD;
&#xD;
               -  Hypertension (&gt;140/90).&#xD;
&#xD;
               -  Asthmatic symptoms within the past 3 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jermaine Jones, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYSPI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 20, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <results_first_submitted>August 25, 2020</results_first_submitted>
  <results_first_submitted_qc>October 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 26, 2020</results_first_posted>
  <last_update_submitted>November 8, 2020</last_update_submitted>
  <last_update_submitted_qc>November 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Jermaine Jones</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Neurobiology (in Psychiatry)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methamphetamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 10, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT03226223/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Naltrexone 0mg First, Then Naltrexone 50mg</title>
          <description>This aim assess the effects of pretreatment with 0 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).&#xD;
Intranasal Methamphetamine: Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)</description>
        </group>
        <group group_id="P2">
          <title>Naltrexone 50mg First, Then Naltrexone 0mg</title>
          <description>This aim assess the effects of pretreatment with 50 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).&#xD;
Intranasal Methamphetamine: Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline data are provided for participants who completed both conditions N=14.</population>
      <group_list>
        <group group_id="B1">
          <title>Naltrexone 0mg First, Then Naltrexone 50mg</title>
          <description>This aim assess the effects of pretreatment with 0 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).&#xD;
Intranasal Methamphetamine: Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)</description>
        </group>
        <group group_id="B2">
          <title>Naltrexone 50mg First, Then Naltrexone 0mg</title>
          <description>This aim assess the effects of pretreatment with 50 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).&#xD;
Intranasal Methamphetamine: Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.1" spread="6.5"/>
                    <measurement group_id="B2" value="31.7" spread="9.3"/>
                    <measurement group_id="B3" value="33.4" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Methamphetamine Self-Administration</title>
        <description>To assess the reinforcing effects of methamphetamine, participants complete a drug self-administration procedure. The outcome measure for this procedure is the number of operant responses (clicks on a mouse) participant are willing to make in order to receive drug (methamphetamine).</description>
        <time_frame>1 day.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone 0 mg</title>
            <description>This aim assess the effects of pretreatment with 0 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).&#xD;
Intranasal Methamphetamine: Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone 50 mg</title>
            <description>This aim assess the effects of pretreatment with 50 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).&#xD;
Intranasal Methamphetamine: Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)</description>
          </group>
        </group_list>
        <measure>
          <title>Methamphetamine Self-Administration</title>
          <description>To assess the reinforcing effects of methamphetamine, participants complete a drug self-administration procedure. The outcome measure for this procedure is the number of operant responses (clicks on a mouse) participant are willing to make in order to receive drug (methamphetamine).</description>
          <units>Clicks on a computer mouse</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8890" spread="3509"/>
                    <measurement group_id="O2" value="7116" spread="3080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive Subjective Effects of Methamphetamine.</title>
        <description>Participant ratings of methamphetamine &quot;Liking,&quot; on a 100 mm visual analog scale. Participants are asked to indicate on a 100 mm line the extent to which they agree with the description of the drug provided. The 0 mm end of the line indicates &quot;Not at All,&quot; while the 100 mm indicates &quot;Extremely.&quot;</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone 0 mg</title>
            <description>This aim assess the effects of pretreatment with 0 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).&#xD;
Intranasal Methamphetamine: Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)</description>
          </group>
          <group group_id="O2">
            <title>Naltrexone 50 mg</title>
            <description>This aim assess the effects of pretreatment with 50 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).&#xD;
Intranasal Methamphetamine: Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Subjective Effects of Methamphetamine.</title>
          <description>Participant ratings of methamphetamine &quot;Liking,&quot; on a 100 mm visual analog scale. Participants are asked to indicate on a 100 mm line the extent to which they agree with the description of the drug provided. The 0 mm end of the line indicates &quot;Not at All,&quot; while the 100 mm indicates &quot;Extremely.&quot;</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6" spread="38.9"/>
                    <measurement group_id="O2" value="57.2" spread="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 Month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Naltrexone 0 mg</title>
          <description>This aim assess the effects of pretreatment with 0 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).&#xD;
Intranasal Methamphetamine: Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)</description>
        </group>
        <group group_id="E2">
          <title>Naltrexone 50 mg</title>
          <description>This aim assess the effects of pretreatment with 50 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).&#xD;
Intranasal Methamphetamine: Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jermaine Jones</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>6467746113</phone>
      <email>jermaine.jones@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

